

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9960)

VOLUNTARY ANNOUNCEMENT
PROPOSED ACQUISITIONS OF EQUITY INTERESTS IN
THE TARGET COMPANIES

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company wishes to update the shareholders of the Company (the “**Shareholders**”) and potential investors that it is in the course of negotiation to acquire 100% equity interest in Guangzhou Kangcheng Weiye Biotechnology Co., Ltd.* (廣州康丞唯業生物科技有限公司) and AnchorDx Inc., respectively (collectively, the “**Proposed Acquisitions**”).

As of the publication of this announcement, the Company has not entered into any legally binding transaction documents in relation to the Proposed Acquisitions. Based on the latest information in respect of the Proposed Acquisitions that is available, the Proposed Acquisitions are expected to constitute a discloseable transaction of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Company will make further announcements as and when necessary in compliance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, September 20, 2024

As of the date of this announcement, the Board comprises Dr. HUANG Shiang, Mr. TU Zanbing and Ms. CHAI Haijie as executive Directors, Mr. HUANG Zuie-Chin, Mr. PENG Wei and Ms. HUANG Lu as non-executive Directors, and Dr. YAO Shanglong, Dr. XIA Xinping and Mr. GU Huaming as independent non-executive Directors.

* For identification purposes only